Evidence map›Paper›PMID 26379236›Full record

ArticlePloS one2015

Inhibition of Inactive States of Tetrodotoxin-Sensitive Sodium Channels Reduces Spontaneous Firing of C-Fiber Nociceptors and Produces Analgesia in Formalin and Complete Freund's Adjuvant Models of Pain.

David J Matson, Darryl T Hamamoto, Howard Bregman, Melanie Cooke, Erin F DiMauro, Liyue Huang, Danielle Johnson, Xingwen Li, Jeff McDermott, Carrie Morgan and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Inhibition of NaRSC medicinal chemistry · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

David J MatsonDepartment of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America.
Darryl T HamamotoDepartment of Diagnostics and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, Minnesota, United States of America.
Howard BregmanDepartment of Medicinal Chemistry, Amgen Inc., Cambridge, Massachusetts, United States of America.
Melanie CookeDepartment of Pharmaceutics Research & Development, Amgen Inc., Cambridge, Massachusetts, United States of America.
Erin F DiMauroDepartment of Medicinal Chemistry, Amgen Inc., Cambridge, Massachusetts, United States of America.
Liyue HuangDepartment of Pharmacokinetics & Drug Metabolism, Amgen Inc., Cambridge, Massachusetts, United States of America.
Danielle JohnsonDepartment of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America.
Xingwen LiDepartment of Pharmacokinetics & Drug Metabolism, Amgen Inc., Cambridge, Massachusetts, United States of America.
Jeff McDermottDepartment of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America.
Carrie MorganDepartment of Pharmaceutics Research & Development, Amgen Inc., Cambridge, Massachusetts, United States of America.
Ben WilenkinDepartment of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America.
Annika B MalmbergDepartment of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America.
Stefan I McDonoughDepartment of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America.
Donald A SimoneDepartment of Diagnostics and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, Minnesota, United States of America.
Amgen (United States) · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While genetic evidence shows that the Nav1.7 voltage-gated sodium ion channel is a key regulator of pain, it is unclear exactly how Nav1.7 governs neuronal firing and what biophysical, physiological, and distribution properties of a pharmacological Nav1.7 inhibitor are required to produce analgesia. Here we characterize a series of aminotriazine inhibitors of Nav1.7 in vitro and in rodent models of pain and test the effects of the previously reported "compound 52" aminotriazine inhibitor on the spiking properties of nociceptors in vivo. Multiple aminotriazines, including some with low terminal brain to plasma concentration ratios, showed analgesic efficacy in the formalin model of pain. Effective concentrations were consistent with the in vitro potency as measured on partially-inactivated Nav1.7 but were far below concentrations required to inhibit non-inactivated Nav1.7. Compound 52 also reversed thermal hyperalgesia in the complete Freund's adjuvant (CFA) model of pain. To study neuronal mechanisms, electrophysiological recordings were made in vivo from single nociceptive fibers from the rat tibial nerve one day after CFA injection. Compound 52 reduced the spontaneous firing of C-fiber nociceptors from approximately 0.7 Hz to 0.2 Hz and decreased the number of action potentials evoked by suprathreshold tactile and heat stimuli. It did not, however, appreciably alter the C-fiber thresholds for response to tactile or thermal stimuli. Surprisingly, compound 52 did not affect spontaneous activity or evoked responses of Aδ-fiber nociceptors. Results suggest that inhibition of inactivated states of TTX-S channels, mostly likely Nav1.7, in the peripheral nervous system produces analgesia by regulating the spontaneous discharge of C-fiber nociceptors.

Indexed as

Action PotentialsAnalgesiaAnalgesicsAnimalsFormaldehydeFreund's AdjuvantMaleNAV1.7 Voltage-Gated Sodium ChannelNerve Fibers, UnmyelinatedNociceptorsPainPain ManagementPain MeasurementPatch-Clamp TechniquesRatsRats, Sprague-DawleyAnalgesicsFormaldehydeFreund's AdjuvantNAV1.7 Voltage-Gated Sodium ChannelScn9a protein, ratSodium Channel BlockersTetrodotoxin

Identifiers

PMID26379236
PMCPMC4575030
OpenAlexW2179850034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.